Home > Gastroenterology > ECCO 2020 > Head-to-Head Comparison of Treatments > Effects of vedolizumab versus adalimumab on QoL

Effects of vedolizumab versus adalimumab on QoL

Presented By
Dr E.V. Loftus, Mayo Clinic, USA
Conference
ECCO 2020
Trial
VARSITY
The effects of intravenous vedolizumab versus adalimumab on quality of life (QoL) were compared in a subanalysis of the VARSITY trial. More ulcerative colitis (UC) patients treated with vedolizumab than with adalimumab achieved clinically meaningful improvement and clinical remission, based on the Inflammatory Bowel Disease Questionnaire (IBDQ) scores [1]. VARSITY was the first head-to-head trial comparing the efficacy and safety of biologics in patients with moderately to severely active UC, and was one of the highlights of the 2019 edition of the ECCO-IBD meeting [2,3]. To assess QoL, the IBDQ was used. Clinically meaningful IBDQ improvement was defined as an increase in total score of ≥16 points from baseline to week 52; IBDQ remission was a total score of >170 points at week 52. Results showed a clinically meaningful IBDQ improvement at week 52 in 199/383 patients (52.0%) versus 163/386 (42%) in the vedolizumab and adalimumab group, respectiv...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on